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Abstract — In general, ‘drinkers smoke’, and a high proportion of the alcohol-dependent population is also nicotine-dependent.
Statistically, the majority of alcoholics will die of smoking-related, rather than alcohol-related, disease. This co-dependent sub-
population may have higher levels of nicotine dependence, and ﬁnd smoking cessation more difﬁcult. Major reasons are that
concurrent alcohol use, and/or prior alcohol exposure, may change the reinforcing effects of nicotine, and that each drug becomes
a pharmacological cue for the expectation of the other. If so, then smokers whose nicotine dependence is impacted by alcohol,
represent a large and distinct sub-population in which both the therapeutic and molecular targets for smoking cessation are altered.
This, in turn, has implications for the validity of animal models of nicotine reinforcement, and for the development of novel smoking
cessation medications. It is no longer possible to ignore the fact that the two most prevalent and damaging addictive drugs in our
society are very commonly used by the same individuals. Without a better understanding of the psychological and pharmacological
interactions between alcohol and nicotine that impact dependence, we cannot hope to provide appropriate medications for this large
and problematic patient group. Our intention in this opinion overview is to use the current literature to provide a framework for
future studies into the impact of alcohol use on the reinforcing effects of nicotine.
CONTRIBUTION OF SMOKING TO MORBIDITY
ASSOCIATED WITH ALCOHOL DEPENDENCE
In the alcohol dependent population, smoking is commonly
estimated in excess of 80% (Bobo, 1992; Miller and Gold,
1998) and it is estimated that smokers have a signiﬁcantly
increased risk (between 4 and 10%) for developing alco-
hol use disorders (see DiFranza and Guerrera, 1990; Grant
et al., 2004). This ‘co-dependence’ has a major effect on
morbidity because there are many diseases, including sev-
eral cancers (Sasco et al., 2004), as well as cardiovascular
disease, in which smoking is the major risk factor (Benowitz,
2003), and in which the use of alcohol provides added risk.
Indeed, because of the prevalence of smoking-related mor-
bidity, alcoholics are more likely to die of smoking-related
disease rather than directly from alcohol-related medical dis-
order (see, Hurt et al., 1996; Hurt and Patten, 2003). Given
this situation it is essential to address both dependencies
when they co-exist. This overview and opinion paper con-
siders whether this population of ‘alcoholic smokers’ should
be considered as distinct from ‘smokers’ in relation to treat-
ment for their nicotine dependence. However, there is an
additional factor to be considered, because this focus on
adult prevalence neglects other ways in which alcohol expo-
sure or use during development might alter nicotine addic-
tion. For example, there is a strong relationship between use
of alcohol in early adolescence and prevalence of smoking
in adulthood (Paavola et al., 2004). Similarly, fetal alco-
hol exposure via maternal drinking is reported to be asso-
ciated with an increased incidence of drug abuse includ-
ing nicotine dependence in adulthood (Yates et al., 1998;
Obot et al., 2001). Of course, these are merely associa-
tions, and common genetic or environmental factors that
*Author to whom correspondence should be addressed at: Kentucky Tobacco
Research and Development Center, Room 122, Cooper & University Drives,
Lexington, KY 40546-0236, USA. Tel: 859 257-1085;
E-mail: jlittlet@uky.edu
predispose to drug use in general almost certainly con-
tribute. However, this does not invalidate the hypothesis that
chronic alcohol use, and/or developmental exposure to alco-
hol, impacts nicotine dependence, and there is ample evidence
for this (see below). Effective medications that target ‘inter-
active’ risk could have a signiﬁcant impact on morbidity
in both the alcohol dependent, and the nicotine dependent,
populations.
This paper is not intended as a traditional review of the
literature regarding the pharmacological or behavioral over-
lap between nicotine and alcohol dependence. Rather, it is to
draw attention to some of the complexities that are involved
and to discuss issues which merit further study. These issues
range from concerns of shared etiologies, differential trajec-
tories (including gene/environment interactions) and under-
studied issues such as individual differences in pharmacoki-
netic/dynamics and pharmacogenetics. It is hoped that this
will help emphasize the need for molecular, pharmacological
and behavioral studies of risk, prevention, intervention and
treatment for this population.
DOES ALCOHOL USE OR EXPOSURE CREATE A
DIFFERENT KIND OF SMOKER?
If the co-incidence of smoking and drinking in adults were
the result of a common predisposition to drug dependence, it
should affect the smoking and drinking populations equally.
However, this relation is asymmetric. Why this is the case
is not certain but may be explained, in part, due to differ-
ential rates of these behaviors/disorders. It is estimated that
∼>80% of individuals with a diagnosis of alcohol depen-
dence also smoke heavily (DiFranza and Guerrera, 1990;
Bobo, 1992). In contrast, although the risk of alcohol use
disorders is increased among heavy smokers, the estimated
prevalence is only about ∼40% (DiFranza and Guerrera,
1990; Grant et al., 2004). Mathematically, this pattern sug-
gests that individuals who continue to use alcohol in adult-
hood are signiﬁcantly more likely to continue to smoke than
 The Author 2007. Published by Oxford University Press on behalf of the Medical Council on Alcohol. All rights reserved
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those who do not. This is supported directly by ﬁndings show-
ing that adults who also use alcohol have higher levels of
nicotine dependence (Marks et al., 1997; Horn et al., 2000;
Hughes et al., 2000; John et al., 2003; Hertling et al., 2005)
and report greater difﬁculty in quitting smoking (DiFranza
and Guerrera, 1990; Novy et al., 2001). In alcohol depen-
dent individuals in treatment, the severity of nicotine depen-
dence is associated with greater alcohol craving (Hillemacher
et al., 2006) and these characteristics can also extend to indi-
viduals who were heavy drinkers, but who have become
abstinent (Junghanns et al., 2000; Currie et al., 2001; John
et al., 2003). Thus, based on prevalence in adults, the poten-
tial impact of prior or concurrent alcohol use on nicotine
dependence must be in excess of 40% of the total smoking
population.
Turning once again to developmental factors, the relation-
ships between developmental alcohol exposure and adult nico-
tine dependence remain after controlling for potential genetic
and environmental confounds. For example, the effects of
fetal alcohol exposure on adult nicotine and drug dependence
were observed in adopted-away offspring, and remained even
when the characteristics of the biological parents were fac-
tored out (Yates et al., 1998). The ﬁndings therefore suggest
that exposure of the developing CNS to alcohol may increase
susceptibility to nicotine dependence. This is strongly sup-
ported by studies in which early postnatal chronic exposure
of rats to ethanol resulted in a marked increase in the reinforc-
ing properties of nicotine in adolescence (Rogers et al., 2004).
In humans, it is difﬁcult to assess the relative importance of
fetal, adolescent and adult exposure, because developmen-
tal alcohol exposure also increases the use of alcohol in the
adult (Novy et al., 2001; John et al., 2003). However, mod-
erate drinking in pregnancy remains at about 10% (Ofﬁce of
Applied Studies, 2004), and adolescent experimentation with
alcohol is common (O’Malley et al., 1998), thus, it is very
likely that all of these periods of exposure are important. In
summary, nicotine addiction is directly or indirectly inﬂu-
enced by alcohol use for at least 40% of the nicotine addicted
population. If alcohol use alters therapeutic targets for smok-
ing cessation (see below) then this sub-population has to be
considered separately in deciding treatment options, and in
the development of new medications. Furthermore, if nicotine
exposure increases risk for alcohol craving and/or use, it may
be important to reduce exposure directly and/or the smoking-
related cues among alcoholics initiating recovery. However,
concluding that ALL nicotine use/exposure is negative may
be premature; particularly in light of data suggesting that
acute nicotine administration may have a differential impact
(improve) cognitive performance in alcoholics compared to
non-alcoholic smokers, at least early in recovery (Ceballos
et al., 2005, 2006).
IMPACT OF ALCOHOL USE ON REINFORCING
EFFECTS OF NICOTINE
Although psychosocial, environmental and genetic reasons
are important in the incidence of co-dependence on alco-
hol and nicotine, the development of appropriate treatments
speciﬁcally requires an understanding of the pharmacologi-
cal interactions between reinforcing effects of these drugs.
The key mechanisms are those by which alcohol use, or
developmental exposure, modiﬁes the reinforcing effects of
nicotine. First, concurrent use of alcohol with nicotine (in
which both drugs are present in the brain at the same time) is
very common, and some reasons may be pharmacological and
impact reinforcement. For example, the stimulant effects of
nicotine may offset some of the ‘aversive’ acute CNS depres-
sant effects of alcohol (Schaefer and Michael, 1992). There is
also evidence that the more permanent cognitive deﬁcits asso-
ciated with chronic alcohol use can be reversed by nicotine
administration (Meyerhoff et al., 2006) making the cognition-
enhancing effects of nicotine potentially more reinforcing than
they would be in non-alcoholic smokers. However, not all use
of nicotine is co-incident with alcohol use, even in individu-
als who use the drugs ‘concurrently’, and the temporal pat-
tern may inﬂuence the reinforcement obtained. For example,
anxiety, and hyperalgesia occur during an alcohol hangover
(McKinney and Coyle, 2006), and cigarettes smoked before
drinking resumes may relieve this negative affect by virtue of
the ‘secondary’ pharmacological actions of nicotine (which
include anxiolysis and potent analgesia) (Brioni et al., 1993).
Similar negative affect occurs during alcohol withdrawal, and
it is a common observation that smoking escalates during
attempts to quit alcohol. It is possible that cigarette smoking
serves as a ‘substitute reinforcer’ during periods of alco-
hol abstinence (see Bickel et al., 1995 for discussion) but
this is likely an oversimpliﬁcation. For example, Mello and
colleagues (Mello et al., 1980) found that cigarette smoking
served as a complementary reinforcer, with cigarette smoking
decreasing as alcohol intake decreased. Similarly, Rohsenow
and colleagues (Rohsenow et al., 1997) found that in recover-
ing male alcoholics, exposure to alcohol cues resulted in sig-
niﬁcantly increased urge to drink, and urge to smoke (although
smoking itself did not increase).
Additionally, although we often do not understand the
mechanisms, chronic alcohol use may be associated with
psychiatric illness that impacts the reinforcement provided
by nicotine. For example, major depression is commonly
associated with alcohol dependence (Modesto-Lowe and
Kranzler, 1999) and may make the mood-elevating effects
of nicotine more salient. Clinical depression is certainly also
a major negative factor in attempts at smoking cessation
(Glassman et al., 2001; Burgess et al., 2002; Blalock et al.,
2006) and this might make a treatment with antidepressant
properties, such as bupropion, particularly effective in this
signiﬁcant sub-population (‘depressed alcoholic smokers’)
(Hayford et al., 1999; Tonstad, 2002). These limited examples
illustrate a general principle, individuals who smoke and drink
may obtain different reinforcing effects of nicotine from those
who do not also use alcohol. If so, the therapeutic targets for
smoking cessation in this sub-population are also likely to be
different.
To move from purely ‘pharmacological’ considerations,
classical conditioning is recognized as playing a major role in
the addictive properties of cigarette smoking, and concurrent
use of alcohol and nicotine may make each become a ‘cue’
for the expectation of the other. Thus, smoking cessation
may be confounded by ‘craving’ for nicotine initiated by
use of alcohol (Gulliver et al., 1995; Field et al., 2005) but
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the relation is complex. As above, some theories predict that
nicotine use should be increased during alcohol deprivation
(Tiffany, 1990) whereas others suggest a less reciprocal
relationship (Rohsenow et al., 1997). Whatever theoretical
model is applied, there is little argument that the role of
such pharmacologically and behaviorally conditioned stimuli
is potentially great and may be prolonged, particularly when
conditioning occurs in periods of CNS plasticity, such as
during adolescence (Sullivan and Rudnik-Levin, 2001). Once
again this shifts the important therapeutic target, in this case
toward blunting pharmacological conditioning.
IMPACT OF DEVELOPMENTAL ALCOHOL EXPOSURE
ON REINFORCING EFFECTS OF NICOTINE
Adolescent and fetal drug exposure can impact behavior and
mood throughout life. For example, fetal alcohol exposure
(via maternal use), or heavy use in adolescence, inﬂuence
attention, pain sensation, and anxiety in adulthood and are
also strong risk factors for adult nicotine addiction (e.g.
Hill et al., 2000; Hellstrom-Lindahl and Nordberg, 2002;
Adriani et al., 2003; Novak et al., 2003). Once again, alcohol
exposure might modify the reinforcing effects of nicotine. For
example, attention deﬁcit hyperactivity disorder (ADHD) is
commonly associated with fetal alcohol exposure (Mattson
and Riley, 1998). ADHD is also strongly associated with
adolescent nicotine use (Sullivan and Rudnik-Levin, 2001)
which might reﬂect a form of ‘self-medication’ in which
attentional effects of nicotine are speciﬁcally reinforcing (see
Upadhyaya, 2006). Other types of reinforcement may also
achieve higher salience. In animal studies, early postnatal
exposure of rat pups to alcohol produces a hyperalgesia that
extends into adolescence. Nicotine is now a more effective
analgesic, and has greater reinforcing properties in this
group than in adolescent controls (Rogers et al., 2004). We
hypothesize that ‘developmental exposure’ to alcohol may
change the strength and character of subsequent reinforcing
properties of nicotine. If so, then alcohol use in adolescence,
and/or exposure in utero, may impact nicotine addiction, even
in smokers who do not currently use alcohol.
THERAPEUTIC TARGETS AND MODELS FOR
MEDICATIONS DEVELOPMENT
These theoretical considerations of interactions between rein-
forcing effects of alcohol and nicotine suggest two types of
novel therapeutic target. One is a partial substitution for alco-
hol by nicotine during periods in which alcohol is negatively
reinforcing, and the other is cross-conditioning between alco-
hol and nicotine. The ﬁrst suggests that some potentially
reinforcing effects of nicotine (stimulation, analgesia, anxi-
olysis, attention) may acquire greater value during concur-
rent use of, or following developmental exposure to, alcohol.
Currently these therapeutic targets are almost ignored in the
development of smoking cessation therapy. Thus, in most ani-
mal models that are used for medication development, the
focus is on ‘positive reinforcement’ in otherwise untreated
laboratory animals. Under these conditions, nicotine acts as a
‘very weak positive reinforcer’, for example, unlike cocaine,
amphetamines and opiates, it does not induce strong condi-
tioned place preference (CPP) (Fudala and Iwamoto, 1986;
Iwamoto, 1990; Shoaib et al., 1994). This does not reﬂect
the strength of nicotine dependence in humans (regardless
of alcohol use), and casts some doubt on the face and pre-
dictive validity of the models. If the reinforcing properties
of nicotine in humans include the ‘secondary’ pharmacologi-
cal actions of nicotine, then it would improve face validity
if animal screens could be developed to reﬂect this. One
way to do this would be to include alcohol treatment in the
models. Thus, as described above, alcohol exposure to neona-
tal rats both induces hyperalgesia, and markedly increases
nicotine-induced CPP in adolescence (Rogers et al., 2004).
Consequently, a case could be made for adding developmen-
tal alcohol exposure to animal screens for medications for
nicotine addiction. Whether this would improve the predictive
validity of such screens and models remains to be seen! It cer-
tainly would improve the face validity for the large proportion
of potential patients who use alcohol and nicotine together.
However, not only are the therapeutic targets of reinforcement
and conditioning shifted in this sub-population, the molecular
targets may also be altered.
IMPACT OF ALCOHOL USE ON PRIMARY
MOLECULAR MECHANISMS OF NICOTINE
REINFORCEMENT
The positive reinforcing effects of nicotine are primar-
ily mediated by brain nicotinic acetylcholine receptors
(nicAChRs). Nicotine has a high afﬁnity speciﬁcally for
nicAChRs of the alpha4/beta2 subtype, and the diversity of
effects of nicotine is partly because alpha4/beta2 nicAChRs
are widespread in the brain, and sub-serve several functions.
However, the brain concentrations of nicotine achieved in
smokers are about two orders of magnitude greater than the
afﬁnity for alpha4/beta2 nicAChRs (Brody et al., 2006), thus
activating several other nicAChR subtypes. Indeed, the high
afﬁnity of nicotine for alpha4/beta2 receptors may desensi-
tize this entire subtype population in the brain during smok-
ing, making agonist properties of nicotine in smoking more
pronounced on nicAChRs other than the alpha4/beta2 sub-
type (Brody et al., 2006)! These other receptor subtypes are
also differentially involved in the behavioral functions of the
cholinergic nervous system in the brain. Once again, these
many pharmacological actions may acquire more reinforcing
‘value’ in different mood or physiological states, or when
other drugs are present, or during withdrawal from drugs
(including nicotine itself). As above, if after alcohol exposure,
nicotine analgesia acquires reinforcing value, then a subtype-
speciﬁc nicAChR ligand with greater (or more prolonged)
analgesic properties may be a more effective ‘substitute’.
Additionally, if alcohol exposure ‘up-regulates’ a speciﬁc sub-
type of nicAChR, then ligands selective for this subtype may
be more effective in this sub-population. Since alcohol and
nicotine both acutely affect alpha4/beta2 subunit-containing
nicAChRs (e.g. Owens et al., 2003) chronic use of either
drug might modify the nicAChR population, producing a
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major effect on the reinforcing effects of nicotine. For alco-
hol, the evidence for this is abundant, but confusing (Booker
and Collins, 1997; Covernton and Connolly, 1997; Marsza-
lec et al., 1999), with increases and decreases in nicAChRs
in different brain areas, under different conditions. Of most
relevance here, there has been surprisingly little research on
the effects of chronic alcohol exposure on nicAChR subtype
density in those brain areas believed to mediate reinforcing
effects of nicotine. Conversely, chronic nicotine exposure has
been repeatedly shown to up-regulate alpha4/beta2 nicAChRs
(Pauly et al., 1996), but we were unable to ﬁnd any research
on the combined effects of alcohol and nicotine exposure on
the density of nicAChR subtypes in different brain areas. This
kind of information seems essential if smoking cessation med-
ications are to be effectively targeted on the co-dependent
population.
IMPACT OF ALCOHOL ON SECONDARY
MOLECULAR MECHANISMS OF NICOTINE
REINFORCEMENT
In common with all drugs of dependence, the positive rein-
forcing effects of nicotine are believed to be mediated by
enhanced effects of dopamine (DA) released in the nucleus
accumbens from neurons originating in the ventral tegmen-
tal area (VTA) (Liu et al., 2006). In the case of nicotine,
DA release in the accumbens is partly mediated by nicotine-
induced presynaptic glutamate release acting on N-methyl-D-
aspartate receptors (NMDARs) (Kosowski et al., 2004). Fur-
ther, both alcohol and nicotine dependence are associated
with marked elevations in circulating homocysteine, a potent
NMDAR antagonist (Jacques et al, 2001; Bleich et al., 2005).
In consequence, long-term effects of alcohol and nicotine on
NMDARs have implications for the reinforcing effects of
nicotine. Thus, chronic alcohol treatment during development
or in adulthood, can alter NMDAR numbers, and/or function,
and/or subunit expression (e.g. Lovinger, 1996; Tsai, 1998;
Hoffman 2003), The potential for pharmacological interac-
tions between alcohol and nicotine at this molecular target
is high, because chronic nicotine exposure may have similar
effects to alcohol on NMDARs (Trujillol and Akil, 1995).
Despite these remarkable coincident effects of alcohol and
nicotine on glutamate neurotransmission, very little research
has focused on effects of either, or both, drugs on alter-
ations in glutamate receptors in the brain regions that subserve
reinforcement. Since the same receptors are also involved in
classical conditioning (see below) any such alterations take on
even greater signiﬁcance as molecular therapeutic targets. In
addition to glutamate, the opioid transmitter system also reg-
ulates the dopaminergic neurons from the VTA to the nucleus
accumbens. In the case of positive reinforcement caused by
alcohol there is little doubt that release of endogenous opi-
oids plays a role (and this probably underlies the efﬁcacy
of the opioid antagonist, naltrexone, in relapse). For nico-
tine, the situation is much less clear. There is evidence that
opioid antagonists can reduce nicotine reinforcement (Brauer
et al., 1999; Almeida et al., 2004; Rukstalis et al., 2005) and
some analgesic effects of nicotine are also sensitive to opi-
oid antagonists (Simons et al., 2005). Both ﬁndings suggest
that nicotine causes release of endogenous opioids (Olive
et al., 2001), but an alternative possibility is that some opi-
oid antagonists inhibit some nicAChRs (Almeida et al., 2004).
Regardless of whether nicotine directly affects the opioid sys-
tem, alcohol-induced alterations in opioid receptor numbers
and distribution might have a general effect on reinforcing
mechanisms that would impact those of nicotine. If so, opi-
oid receptor antagonists might have a therapeutic role in
co-dependence as well as in alcohol dependence (see below).
MOLECULAR TARGETS FOR SMOKING CESSATION
Nicotinic receptors (nicAChRs)
As above, there are several potentially reinforcing effects
of nicotine involving different nicAChR subtypes. Which
subtypes might be speciﬁcally involved in reinforcement in
patients whose nicotine use is impacted by alcohol use or
exposure is largely unknown. As regards medications devel-
opment, one can say only that alcohol use, or prior exposure,
may alter the therapeutic targets (i.e. the reinforcing effects
of nicotine) and that these targets are likely related to differ-
ent populations of molecular targets (i.e. nicAChR subtypes).
Currently these subtleties are ignored. Thus nicotine depen-
dence is usually treated with nicotine itself (via a more slowly
absorbed, less toxic, route than smoking) or bupropion (an
antidepressant with nicAChR antagonist properties). Given
the complexities inherent in nicAChR desensitization, and the
pharmacokinetics of nicotine during smoking, it is uncertain
whether the efﬁcacy of these treatments in smoking cessa-
tion is due to nicotine antagonism, or substitution. However,
for medications development this does not matter—novel
ligands for the nicAChR might be efﬁcacious by either or
both of these mechanisms. What we need in order to answer
these questions is a battery of subtype-selective nicAChR ago-
nists and antagonists that can be assessed for their ability to
inhibit different aspects of nicotine dependence. For example,
recent evidence from alpha7-nicAChR ‘knock-out’ mice sug-
gests strongly that this receptor subtype is crucially implicated
in the nicotine physical withdrawal syndrome (Grabus et al.,
2005). However, without highly selective alpha7-ligands, this
cannot be conﬁrmed pharmacologically, and cannot inform
a medication development program. To target nicAChRs for
smoking cessation in alcohol dependent patients we need
to know which receptor subtypes are responsible for which
aspect of nicotine dependence, we need to know how these
subtypes are altered by alcohol exposure, and we need the
right pharmacological tools to evaluate therapeutic potential.
Currently we have none of these!
Glutamate receptors
Another molecular target for smoking cessation is suggested
by the perceived importance of pharmacological condition-
ing in relapse mechanisms involving co-dependence. Classi-
cal conditioning, including cue-induced relapse, is generally
believed to involve glutamate transmission in the extended
amygdala (Weiss and Koob, 2001; Littleton and Zieglgans-
berger, 2003), with a ﬁnal impact on reinforcement via glu-
tamate terminals in the nucleus accumbens (Saulskaya and
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Soloviova, 2004). The major receptors involved in extreme
forms of conditioning, such as ‘conditioned fear’, are glu-
tamate/NMDARs (Biala and Kotlinska, 1999), although evi-
dence is accumulating that metabotropic glutamate receptors
(e.g. mGluR5s) are also involved (Lin et al., 2005; Lominac
et al., 2006), perhaps via positive modulation of NMDARs
(Pisani et al., 2001; Marino and Conn, 2002). This makes
the NMDAR (and mGluR5s) a potential therapeutic target,
both for the prevention of acquisition of dependence, and for
prevention of relapse when this is induced by cues associ-
ated with prior drug use. However, the role of NMDARs
in conditioning reﬂects important physiological functions in
learning and memory, making these receptors a problematic
molecular therapeutic target. Nevertheless, ‘inhibitory mod-
ulators’ of the NMDAR, such as the natural product agma-
tine, reduce expression of pathological conditioning without
adversely affecting learning and memory (Papp et al., 2002)
and also inhibit drug self-administration in animals (Bisaga
et al., 2000). Also, in contrast to antagonists such as ketamine,
these ‘NMDAR modulators’ are reportedly without abuse
potential. Inhibitory modulators of NMDARs are therefore of
potential value in reducing the impact of alcohol-conditioned
cues on nicotine dependence. The anti-relapse drug acam-
prosate is believed to act as an indirect inhibitor of NMDAR
function (Littleton and Zieglgansberger, 2003; De Witte et al.,
2005) and is suggested to suppress both protracted alco-
hol withdrawal, and alcohol-conditioned responses that pre-
cipitate relapse (Cole et al., 2000; McGeehan and Olive
2003). Therefore, if either alcohol withdrawal, or alcohol-
conditioned responses, play a role in maintaining nicotine use,
then agents like acamprosate should be of value for smok-
ing cessation in this patient group. Because alcohol exposure
changes NMDAR numbers and composition (see above) the
effects of NMDAR modulators on any kind of cue-induced
reinstatement of nicotine self-administration may also be
altered in this population. We surmise that it is these changes
that may provide the best potential molecular targets for treat-
ment of co-dependence. This possibility has never been tested.
Opioid receptors
In addition to acamprosate (above) the only other current
generally-approved treatments for alcohol dependence are
disulﬁram and naltrexone. The mechanism of disulﬁram is not
predicted to impact smoking, however, since some evidence
implicates the endogenous opioid system in reinforcing effects
of nicotine, it is logical to consider the effect of naltrexone.
The evidence is mixed. Naltrexone has been reported to
have no beneﬁcial effect on smoking cessation (Sutherland
et al., 1995; Wong et al., 1999) or sometimes to have a
small positive effect when combined with the nicotine patch
(Krishnan-Sarin et al., 2003; O’Malley et al., 2006). Two
studies have found this effect only in females (Epstein and
King, 2004; Byars et al., 2005; King et al., 2006). Naltrexone
has also been reported to blunt the effect of smoking cues
during treatment with the nicotine patch (Hutchison et al.,
1999). As regards the effect of naltrexone on smoking
behavior when used as a treatment for alcohol dependence,
one study showed a rather small effect in the direction of
reduced cigarette use (Rohsenow et al., 2003). On balance,
opioid receptors cannot be excluded as a potential therapeutic
target for smoking cessation in alcohol dependent individuals,
but the currently available opioid antagonists seem not to be
very effective.
SUMMARY AND CONCLUSIONS
A major sub-group of the nicotine-addicted population, per-
haps the majority, is affected by prior alcohol exposure, or
current alcohol use. Despite this, most medications develop-
ment ignores this possibility, and indeed there is very little
basic research into the interactions between the reinforcing
effects of these two most common drugs of dependence.
Traditionally the argument has been that we do not know
enough about reinforcing mechanisms of either drug to begin
to study them together. However, this is no longer the case,
and we submit that one cannot understand the reinforcing
effects of either drug in humans UNLESS one considers
them together! This review suggests that the sub-population
of smokers who are also alcohol dependent requires special
consideration because the strength and character of nicotine
addiction may be altered. Successful treatment of their alcohol
dependence is highly desirable, but this is a hollow victory if
the abstinent alcoholic then dies of smoking-related disease.
Smoking does kill alcoholics, and it is certainly about time
that we tried to do something about it!
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